Welcome to our dedicated page for iSpecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen stock.
iSpecimen Inc., headquartered in Lexington, MA, is a leading marketplace for human biospecimens. The company provides researchers with the specimens they need from the patients they want through its innovative iSpecimen Marketplace. This online platform connects healthcare organizations with access to patients and specimens with scientists in need of these vital resources.
Utilizing proprietary, cloud-based technology, iSpecimen enables researchers to intuitively search for specimens across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. This system allows for easy and compliant access to specimens, facilitating scientific discovery and advancing healthcare for all.
iSpecimen stands out by offering a unique value proposition to both researchers and partner sites. Researchers gain the necessary resources to drive their studies, while partner sites can contribute to biomedical discovery and benefit financially. The company caters to a global market, with operations spanning the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with the majority of its revenue coming from the Americas.
In recent news, iSpecimen has achieved a sequential quarterly revenue growth of 75%, driven by enhanced operational efficiencies and new business initiatives. The company continues to expand its network by adding new suppliers and reinforcing existing relationships to provide researchers with increased access to highly sought-after biospecimens, especially for oncology research. Additionally, iSpecimen is making strides in quality control and assurance through digital AI histopathology services, enhancing data quality and operational efficiency.
For investors and media inquiries, iSpecimen's contacts at KCSA Strategic Communications are available for further information.
iSpecimen (Nasdaq: ISPC), a market leader in providing biospecimens for medical research, announced CEO Tracy Curley's participation at the Aegis Conference from May 2-4, 2023. Curley is scheduled to present on May 4 at 4:30 p.m. ET. The conference will be held virtually, catering to a global audience interested in biospecimen solutions for scientific research.
iSpecimen connects researchers with healthcare specimen providers through its innovative online marketplace, which enables easy access to human biospecimens necessary for medical discovery. The company utilizes proprietary technology that allows users to search for specimens across a vast network of partner healthcare organizations. This strategic engagement at the Aegis Conference highlights iSpecimen's commitment to advancing medical research through improved specimen accessibility.
iSpecimen (Nasdaq: ISPC) announced its financial results for the first quarter ending March 31, 2023, will be reported on May 4, 2023, before market opens. A conference call will be held at 8:30 a.m. ET that day, featuring comments from CEO Tracy Curley. Investors can join the live call by dialing +1-844-826-3033 (U.S. Toll Free) or +1-412-317-5185 (International). The conference call will also be available via audio webcast on iSpecimen's website. A replay of the call will be accessible until May 18, 2023. iSpecimen is a global online marketplace that connects researchers with healthcare specimen providers, aimed at advancing medical research through biospecimen procurement.
iSpecimen reported record quarterly revenue of $3.2 million for Q4 2022, up 28% year-over-year. The company attributed this growth to operational improvements implemented after an in-depth review of its operations.
For the full year 2022, total revenue was approximately $10.4 million, down from $11.1 million in 2021, primarily due to a decrease in COVID-related revenue. Despite a lower cost of revenue, iSpecimen faced increased general and administrative expenses, leading to a net loss of approximately $10.2 million.
The company plans significant investments in technology and strategic initiatives to enhance revenue in 2023.
iSpecimen (Nasdaq: ISPC) has announced that it will release its financial results for the fourth quarter and full year ended December 31, 2022, on March 14, 2023, before market opening. The Company will host a conference call at 8:30 a.m. Eastern Time that day, featuring remarks from CEO Tracy Curley. Interested parties can join via phone or web and will have access to a replay until March 28, 2023. iSpecimen connects scientists needing biospecimens with healthcare providers, utilizing a cloud-based platform.
iSpecimen Inc. (Nasdaq: ISPC) has expanded its Marketplace by adding seven new biospecimen sample providers in the U.S. and Europe. This strategic growth will enhance access to vital biospecimens for research in oncology, autoimmune and cardiovascular diseases. The new providers include a network for rapid blood collection and clinical trial groups contributing diverse biofluid specimens.
These additions allow researchers to reach larger patient populations with varied phenotypes. iSpecimen's ongoing commitment to improving supplier criteria is expected to bolster growth throughout 2023, enabling essential medical research.
FAQ
What is the current stock price of iSpecimen (ISPC)?
What is the market cap of iSpecimen (ISPC)?
What is iSpecimen Inc.?
Where is iSpecimen Inc. headquartered?
How does the iSpecimen Marketplace work?
What kind of specimens does iSpecimen provide?
What recent achievements has iSpecimen made?
Who can benefit from using iSpecimen's services?
What regions does iSpecimen operate in?
How can researchers access iSpecimen's services?
How does iSpecimen ensure quality control?
How can investors get in touch with iSpecimen?
